Resultados de procura - Barbara J. Gitlitz

Limitar resultados
  1. 1
    Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

    Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma por Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Paul Frankel, Barbara J. Gitlitz, Marianna Koczywas, Igor Espinoza‐Delgado, David R. Gandara

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma

    A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma por Barbara J. Gitlitz, Carole Baker, Yvonne Chapman, Heather Allen, Linda D. Bosserman, Ravi Patel, J. Sanchez, Richard Shapiro, Robert A. Figlin

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Renal cell carcinoma with retroperitoneal lymph nodes

    Renal cell carcinoma with retroperitoneal lymph nodes por Allan J. Pantuck, Amnon Zisman, Frederich Dorey, Debby H. Chao, Ken‐ryu Han, Jonathan W. Said, Barbara J. Gitlitz, Arie S. Belldegrun, Robert A. Figlin

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

    Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial por Barbara J. Gitlitz, James Moon, Bonnie S. Glisson, Hans Reimers, Martin J. Bury, Justin D. Floyd, Thomas K. Schulz, P. Kothai Sundaram, Christopher Ho, David R. Gandara

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib por Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

    Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib por Primo N. Lara, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara J. Gitlitz, Tianhong Li, M. Koczywas, Karen L. Reckamp, David R. Gandara

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer por Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas, Barbara J. Gitlitz, Sachdev Thomas, Igor Espinoza‐Delgado, Everett E. Vokes, David R. Gandara, Chandra P. Belani

    Publicado 2009
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium por Nicholas Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev Thomas, Walter M. Stadler, Everett E. Vokes, Hedy L. Kindler

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure t... por Sai‐Hong Ignatius Ou, Thomas K. Lee, Lauren Young, Maria Y. Fernandez-Rocha, Dean Pavlick, Alexa B. Schrock, Viola W. Zhu, Jeffrey C. Milliken, Siraj M. Ali, Barbara J. Gitlitz

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy

    IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy por Solange Peters, A.W. Kim, Benjamin Solomon, David R. Gandara, Rafał Dziadziuszko, Alessandro Brunelli, Marina Chiara Garassino, Martin Reck, L. Wang, Ikpesu TO, Si Sun, Barbara J. Gitlitz, A. Sandler, Naiyer A. Rizvi

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

    Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small... por Janessa Laskin, Garth Nicholas, Christopher Lee, Barbara J. Gitlitz, Mark Vincent, Yvon Cormier, Joe Stephenson, Yee Ung, Rachel E. Sanborn, Bryn Pressnail, F. Warren Nugent, John Nemunaitis, Martin Gleave, Nevin Murray, Desirée Hao

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

    Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer por Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch, Vincent A. Miller, Kwok‐Kin Wong, Barbara J. Gitlitz, Keith D. Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell, Revathi Ananthakrishnan, Susan Quinn, Jean‐Charles Soria

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

    Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epider... por Karen L. Reckamp, Paul Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Shirish M. Gadgeel, Mihaela Cristea, Chandra P. Belani, Edward M. Newman, David R. Gandara, Primo N. Lara

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

    Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors por Adil Daud, Smitha Krishnamurthi, Mansoor N. Saleh, Barbara J. Gitlitz, Mitesh J. Borad, Philip J. Gold, Elena G. Chiorean, Gregory M. Springett, Richat Abbas, Shefali Agarwal, Nathalie Bardy‐Bouxin, Poe‐Hirr Hsyu, Eric Leip, Kathleen Turnbull, Charles Zacharchuk, Wells A. Messersmith

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib

    HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib por S.-H.I. Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Charbel Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, J.S. Ross, P. Stephens, V.A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

    HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib por Sai‐Hong Ignatius Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

    2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSC... por C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, Hongjie Xu, M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

    Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study por Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Allison Holzhausen, Christine M. Lovly, Heather A. Wakelee

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

    Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer por C.A. Carter, Arun Rajan, Corrine Keen, Éva Szabó, Sean Khozin, Adam D. Thomas, Christina Brzezniak, Udayan Guha, L. Austin Doyle, Seth M. Steinberg, Liqiang Xi, Mark Raffeld, Yusuke Tomita, Min-Jung Lee, S. Lee, Jane B. Trepel, Karen L. Reckamp, S. Koehler, Barbara J. Gitlitz, Ravi Salgia, David Gandara, Everett E. Vokes, Giuseppe Giaccone

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    <i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer

    <i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer por Kartik Konduri, Jean‐Nicolas Gallant, Young Kwang Chae, Francis J. Giles, Barbara J. Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K. Owonikoko, Vijay Peddareddigari, Suresh S. Ramalingam, Satyanarayan K. Reddy, Beth Eaby‐Sandy, Tiziana Vavalà, Andrew R. Whiteley, Heidi Chen, Yingjun Yan, Jonathan H. Sheehan, Jens Meiler, Deborah Morosini, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Christine M. Lovly

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: